Reports - CAR T-Cell Therapy Market
HealthcareCAR T-Cell Therapy Market
CAR T-Cell Therapy Market Trends, Growth & Innovations (2025–2035) by Drug Type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Other Drug Types) by Indication (Lymphoma, Acute Lymphocytic Leukemia, Other Indications) by End User (Hospitals, Cancer Treatment Centers) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. Global CAR T-Cell Therapy Market, 2021 - 2035 (USD Million)
3. Global CAR T-Cell Therapy Market - by Drug Type
3.1. By Axicabtagene Ciloleucel
3.2. By Tisagenlecleucel
3.3. By Brexucabtagene Autoleucel
3.4. By Other Drug Types
4. Global CAR T-Cell Therapy Market - by Indication
4.1. By Lymphoma
4.2. By Acute Lymphocytic Leukemia
4.3. By Other Indications
5. Global CAR T-Cell Therapy Market - by End User
5.1. By Hospitals
5.2. By Cancer Treatment Centers
6. Global CAR T-Cell Therapy Market - by region
6.1. North America
6.2. Europe
6.3. Asia Pacific
6.4. Latin America
6.5. Middle East & Africa
7. Market comparative analysis
Chapter 4 North America CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. North America CAR T-Cell Therapy Market, 2021 - 2035 (USD Million)
3. North America CAR T-Cell Therapy Market - by Drug Type
3.1. By Axicabtagene Ciloleucel
3.2. By Tisagenlecleucel
3.3. By Brexucabtagene Autoleucel
3.4. By Other Drug Types
4. North America CAR T-Cell Therapy Market - by Indication
4.1. By Lymphoma
4.2. By Acute Lymphocytic Leukemia
4.3. By Other Indications
5. North America CAR T-Cell Therapy Market - by End User
5.1. By Hospitals
5.2. By Cancer Treatment Centers
Chapter 5 Europe CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. Europe CAR T-Cell Therapy Market, 2021 - 2035 (USD Million)
3. Europe CAR T-Cell Therapy Market - by Drug Type
3.1. By Axicabtagene Ciloleucel
3.2. By Tisagenlecleucel
3.3. By Brexucabtagene Autoleucel
3.4. By Other Drug Types
4. Europe CAR T-Cell Therapy Market - by Indication
4.1. By Lymphoma
4.2. By Acute Lymphocytic Leukemia
4.3. By Other Indications
5. Europe CAR T-Cell Therapy Market - by End User
5.1. By Hospitals
5.2. By Cancer Treatment Centers
Chapter 6 Asia Pacific CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. Asia Pacific CAR T-Cell Therapy Market, 2021 - 2035 (USD Million)
3. Asia Pacific CAR T-Cell Therapy Market - by Drug Type
3.1. By Axicabtagene Ciloleucel
3.2. By Tisagenlecleucel
3.3. By Brexucabtagene Autoleucel
3.4. By Other Drug Types
4. Asia Pacific CAR T-Cell Therapy Market - by Indication
4.1. By Lymphoma
4.2. By Acute Lymphocytic Leukemia
4.3. By Other Indications
5. Asia Pacific CAR T-Cell Therapy Market - by End User
5.1. By Hospitals
5.2. By Cancer Treatment Centers
Chapter 7 Latin America CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. Latin America CAR T-Cell Therapy Market, 2021 - 2035 (USD Million)
3. Latin America CAR T-Cell Therapy Market - by Drug Type
3.1. By Axicabtagene Ciloleucel
3.2. By Tisagenlecleucel
3.3. By Brexucabtagene Autoleucel
3.4. By Other Drug Types
4. Latin America CAR T-Cell Therapy Market - by Indication
4.1. By Lymphoma
4.2. By Acute Lymphocytic Leukemia
4.3. By Other Indications
5. Latin America CAR T-Cell Therapy Market - by End User
5.1. By Hospitals
5.2. By Cancer Treatment Centers
Chapter 8 Middle East & Africa CAR T-Cell Therapy Market - Segment Analysis
1. Overview
2. Middle East & Africa CAR T-Cell Therapy Market, 2021 - 2035 (USD Million)
3. Middle East & Africa CAR T-Cell Therapy Market - by Drug Type
3.1. By Axicabtagene Ciloleucel
3.2. By Tisagenlecleucel
3.3. By Brexucabtagene Autoleucel
3.4. By Other Drug Types
4. Middle East & Africa CAR T-Cell Therapy Market - by Indication
4.1. By Lymphoma
4.2. By Acute Lymphocytic Leukemia
4.3. By Other Indications
5. Middle East & Africa CAR T-Cell Therapy Market - by End User
5.1. By Hospitals
5.2. By Cancer Treatment Centers
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Celgene Corporation (U.S.)
2. Cartesian Therapeutics Inc. (U.S.)
3. Miltenyi Biotech (Germany)
4. Autolus Therapeutics (UK)
5. Caribou Biosciences Inc. (U.S.)
6. Gilead Sciences Inc. (U.S.)
7. Merck & Co. Inc. (U.S.)
8. Intellia Therapeutics (U.S.)
9. Juno Therapeutics Inc. (U.S.)
10. Bristol-Myers Squibb (U.S.)
11. Novartis AG (Switzerland)
12. Bluebird Bio Inc. (U.S.)
13. Sorrento Therapeutics Inc. (U.S.)
14. Pfizer Inc. (U.S.)
15. Cellectis (France)
16. Celyad Oncology (Belgium)
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By